Dynamic Advisor Solutions LLC Purchases 1,221 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Dynamic Advisor Solutions LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.9% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 65,669 shares of the biopharmaceutical company’s stock after purchasing an additional 1,221 shares during the period. Dynamic Advisor Solutions LLC’s holdings in Gilead Sciences were worth $4,810,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in GILD. Tompkins Financial Corp lifted its stake in Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 241 shares during the period. Fortitude Family Office LLC purchased a new stake in Gilead Sciences in the fourth quarter worth $29,000. Private Wealth Management Group LLC purchased a new stake in Gilead Sciences in the fourth quarter worth $29,000. Sachetta LLC purchased a new stake in Gilead Sciences in the fourth quarter worth $30,000. Finally, Rakuten Securities Inc. purchased a new stake in Gilead Sciences in the fourth quarter worth $33,000. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.29% of the stock is currently owned by insiders.

Gilead Sciences Trading Down 1.6 %

Gilead Sciences stock opened at $69.61 on Wednesday. The business has a 50-day simple moving average of $65.84 and a two-hundred day simple moving average of $72.77. The company has a market cap of $86.72 billion, a P/E ratio of 193.36, a P/E/G ratio of 3.01 and a beta of 0.20. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the company posted $1.37 EPS. Analysts predict that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 4.42%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s dividend payout ratio is 855.56%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GILD. Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 price target on shares of Gilead Sciences in a research note on Friday, April 19th. Morgan Stanley lowered their price objective on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 26th. Maxim Group lowered their price objective on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Wednesday, May 1st. Finally, UBS Group lowered their price objective on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Twelve investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $83.47.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.